Effects of the addition of acarbose to insulin and non-insulin regimens in veterans with type 2 diabetes mellitus

Keywords: Diabetes Mellitus, Type 2, Acarbose, Outcome Assessment (Health Care), Clinical Audit, Retrospective Studies, Veterans, United States

Abstract

Objectives: The primary objective of the study was to assess the mean change in hemoglobin A1c (HbA1c) when acarbose was added to insulin and non-insulin regimens in patients with type 2 diabetes mellitus (T2DM). Secondary objectives were to evaluate the discontinuation rate of acarbose, and to assess the number of patients who were placed on insulin despite the addition of acarbose.

Methods: A retrospective chart review was conducted on veterans with T2DM initiated on acarbose between October 1, 2013 and December 31, 2013. To be included, patients must have had a refill history indicating at least 3 months of acarbose use and HbA1c readings within 6 months prior to initiation and after at least 3 months of use. Excluded patients were those with type 1 diabetes mellitus, serum creatinine ≥2 mg/dL at acarbose initiation, or a diagnosis based on ICD-9 codes for an existing gastrointestinal condition or liver cirrhosis. The two-tailed, paired t-test was used for analysis of the primary objective and descriptive statistics were used for all other outcomes.

Results: Of the 146 patients screened, 102 patients were included in the study. Exclusions were primarily due to patients not being on acarbose for at least 3 months (n=43). The average HbA1c before and after acarbose initiation was 9.08% (SD=1.74) and 8.43% (SD=1.74) respectively, with an average HbA1c reduction of 0.65% (n=102, p=0.0005). Forty patients (39.2%) discontinued acarbose after at least 3 months of use. Of the 73 patients not on insulin at the time of acarbose initiation, 19 (26%) were started on insulin therapy despite addition of acarbose.

Conclusion: Acarbose can be considered in patients who may reach their HbA1c goal with minimal HbA1c reduction. However, adverse effects are a limitation to use. Potential risks and benefits should be assessed and discussed with the patient prior to prescribing acarbose.

Downloads

Download data is not yet available.

Author Biography

Sara A. Wettergreen

Department of Pharmacotherapy

Assistant Professor

References

1. Centers for Disease Control and Prevention (US). National diabetes statistics report: Estimates of diabetes and its burden in the United States, 2014. Atlanta (GA): US Department of Health and Human Services; 2014 Available at: http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html (accessed August 12, 2016).

2. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovic L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangenes F. American Association of Clinical Endocrinologists and American College of Endocrinology - Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2015;21(Suppl 1):1-87. doi: 10.4158/EP15672.GL

3. Cefalu WT, Bakris G, Blonde L, Boulton AJ, D’Alessio D, Golden SH, de Groot M, Greene EL, Hu FB, LeRoith D, Moses RG, Rich S, Riddle MC, Rosenstock J, Tamborlane WV Weinger K, Wylie-Rosett J. American Diabetes Association standards of medical care in diabetes 2016: Approaches to glycemic treatment. Diabetes Care. 2016;39(Suppl. 1):S52-S59. doi: 10.2337/dc16-S010

4. Aschner P, Beck-Nielsen H, Bennett P, Boulton A, Colagiuri R, Colagiuri s, Franz M, Gadsby R, Gagliardino JJ, Home P, McGill M, Manley S, Marshall S, Mbanya JC, Neil A, Ramachandran A, Ramaiya K, Roglic G, Schaper N, Siminerio L, Sinclair A, Snoek F, Van Crombrugge P, Vespasiani G, Viswanathan V, International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014;104(1):1-52. doi: 10.1016/j.diabres.2012.10.001

5. Aruganithan G, McKay GA, Fisher M. Drug for diabetes: part 4 acarbose. Br J Cardiol. 2011;18:78-81.

6. Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M, Schimel D, Weiss S, Taylor T, Krol A, Magner J. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes mellitus. Diabetes Care. 1998;21(12):2056-2061.

7. Rosenstock J, Brown A, Fischer J, Jain A, Littlejohn T, Nadeau D, Sussman A, Taylor T, Krol A, Magner J. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care. 1998;21(12):2050-2055.
Published
2016-12-16
How to Cite
1.
Wettergreen SA, Sheth S, Malveaux J. Effects of the addition of acarbose to insulin and non-insulin regimens in veterans with type 2 diabetes mellitus. Pharm Pract (Granada) [Internet]. 2016Dec.16 [cited 2019Jun.16];14(4):832. Available from: https://www.pharmacypractice.org/journal/index.php/pp/article/view/832
Section
Original Research